,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2018', 'fs': 'Jul 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXXu2AP'}, 'Id': 'a0POZ00000FBXXu2AP', 'Event_Date__c': '2018-07-30', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jul 2018', 'Status_History__c': 'a132P000000ArUwQAK'}, 'change': None}]",Jul 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXXv2AP'}, 'Id': 'a0POZ00000FBXXv2AP', 'Event_Date__c': '2019-05-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2019', 'Status_History__c': 'a132P000000Arf0QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that ceftolozane with tazobactam (Zerbaxa) for significant infections due to multidrug-resistant aerobic Gram-negative organisms, including <i>Pseudomonas aeruginosa</i> and extended spectrum beta-lactamase (ESBL)-producing <i>Enterobacteriaceae</i>, be declined.</p>', 'fs': '<p><span style=""font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that ceftolozane with tazobactam (Zerbaxa) for significant infections due to multidrug-resistant aerobic Gram-negative organisms, including <i>Pseudomonas aeruginosa</i> and extended spectrum beta-lactamase (ESBL)-producing <i>Enterobacteriaceae</i>, be declined.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>Ceftolozane with tazobactam (Zerbaxa) for significant infections due to MDROs, including Ps. aeruginosa and ESBL-PE</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ceftolozane is a novel cephalosporin which exerts bactericidal activity through binding to penicillin-binding proteins, resulting in inhibition of bacterial cell-wall synthesis and subsequent cell death. The Subcommittee noted that tazobactam is a beta-lactam structurally related to penicillins.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ceftolozane and tazobactam are supplied as 1 g ceftolozane with 0.5 g tazobactam as powder for reconstitution for administration by IV infusion. The Subcommittee noted that ceftolozane and tazobactam are approved by Medsafe <span style=""color: black;"">for the treatment of adults with complicated intra-abdominal infections (in combination with metronidazole), or for complicated urinary tract infections including pyelonephritis.</span></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the pooled analysis of two phase III, randomised, double-blind trials investigating ceftolozane and tazobactam in patients with complicated urinary tract infections (ASPECT-cUTI trial) or complicated intra-abdominal infections (ASPECT-cIAI trial) which were reported by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27707990"" target=""_blank"">Popejoy et al. (J Antimicrob Chemother. 2017. 72:268-72</a>). The Subcommittee noted that the ASPECT-cUTI regimen was 7 days of ceftolozane with tazobactam compared to levofloxacin, and the ASPECT-cIAI regimen was 4-14 days of ceftolozane with tazobactam plus metronidazole compared to meropenem.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the pooled analysis included 1,346 patients of which 11% had EBSL-PE at baseline. The Subcommittee noted that reported clinical cure rates for patients with ESBL-PE were 97.4% with ceftolozane and tazobactam (<i>P=</i> 0.006) compared to cure rates of 82.6% for levofloxacin (<i>P</i>=0.011) and 88.5% with meropenem (<i>P</i>&gt;0.005). The Subcommittee considered that the randomised trial data demonstrated high clinical cure rates with ceftolozane and tazobactam treatment for complicated urinary tract infections and intra-abdominal infections caused by ESBL-PE.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following evidence for ceftolozane with tazobactam:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28610832"" target=""_blank"">Alatoom et al. Int J Infect Dis. 2017;62:39-43</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594953"" target=""_blank"">Escolà-Vergé et al. Infection. 2018;46:461-58</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29493397"" target=""_blank"">Giacobbe et al. Expert Rev Anti Infect Ther. 2018;16:307-320</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28735046"" target=""_blank"">Pfaller et al. J Glob Antimicrob Resist. 2017;10:186-194</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29039729"" target=""_blank"">Shortridge et al. Microb Drug Resist. 2018;24:563-77.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/25670823"" target=""_blank"">Solomkin et al. Clin Infect Dis. 2015;60:1462-71</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/25931244"" target=""_blank"">Wagenlehner et al. Lancet. 2015;385:1949-56</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29133568"" target=""_blank"">Wi et al. Antimicrob Agents Chemother. 2017;62:e01970-17</a>.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that ceftolozane and tazobactam was safe and well tolerated. The Subcommittee considered that that the main indication for use of ceftolozane and tazobactam would be against <i>Ps. Aeruginosa</i> and that use of this combination of agents may be more suitable than combination treatment using ceftazidime with avibactam against this organism<i>.</i></p>', 'fs': '<p>Ceftolozane with tazobactam (Zerbaxa) for significant infections due to MDROs, including Ps. aeruginosa and ESBL-PE</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ceftolozane is a novel cephalosporin which exerts bactericidal activity through binding to penicillin-binding proteins, resulting in inhibition of bacterial cell-wall synthesis and subsequent cell death. The Subcommittee noted that tazobactam is a beta-lactam structurally related to penicillins.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ceftolozane and tazobactam are supplied as 1 g ceftolozane with 0.5 g tazobactam as powder for reconstitution for administration by IV infusion. The Subcommittee noted that ceftolozane and tazobactam are approved by Medsafe <span style=""color: black;"">for the treatment of adults with complicated intra-abdominal infections (in combination with metronidazole), or for complicated urinary tract infections including pyelonephritis.</span></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the pooled analysis of two phase III, randomised, double-blind trials investigating ceftolozane and tazobactam in patients with complicated urinary tract infections (ASPECT-cUTI trial) or complicated intra-abdominal infections (ASPECT-cIAI trial) which were reported by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27707990"" target=""_blank"">Popejoy et al. (J Antimicrob Chemother. 2017. 72:268-72</a>). The Subcommittee noted that the ASPECT-cUTI regimen was 7 days of ceftolozane with tazobactam compared to levofloxacin, and the ASPECT-cIAI regimen was 4-14 days of ceftolozane with tazobactam plus metronidazole compared to meropenem.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the pooled analysis included 1,346 patients of which 11% had EBSL-PE at baseline. The Subcommittee noted that reported clinical cure rates for patients with ESBL-PE were 97.4% with ceftolozane and tazobactam (<i>P=</i> 0.006) compared to cure rates of 82.6% for levofloxacin (<i>P</i>=0.011) and 88.5% with meropenem (<i>P</i>&gt;0.005). The Subcommittee considered that the randomised trial data demonstrated high clinical cure rates with ceftolozane and tazobactam treatment for complicated urinary tract infections and intra-abdominal infections caused by ESBL-PE.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following evidence for ceftolozane with tazobactam:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28610832"" target=""_blank"">Alatoom et al. Int J Infect Dis. 2017;62:39-43</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594953"" target=""_blank"">Escolà-Vergé et al. Infection. 2018;46:461-58</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29493397"" target=""_blank"">Giacobbe et al. Expert Rev Anti Infect Ther. 2018;16:307-320</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28735046"" target=""_blank"">Pfaller et al. J Glob Antimicrob Resist. 2017;10:186-194</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29039729"" target=""_blank"">Shortridge et al. Microb Drug Resist. 2018;24:563-77.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/25670823"" target=""_blank"">Solomkin et al. Clin Infect Dis. 2015;60:1462-71</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/25931244"" target=""_blank"">Wagenlehner et al. Lancet. 2015;385:1949-56</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29133568"" target=""_blank"">Wi et al. Antimicrob Agents Chemother. 2017;62:e01970-17</a>.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that ceftolozane and tazobactam was safe and well tolerated. The Subcommittee considered that that the main indication for use of ceftolozane and tazobactam would be against <i>Ps. Aeruginosa</i> and that use of this combination of agents may be more suitable than combination treatment using ceftazidime with avibactam against this organism<i>.</i></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee reviewed the following applications for salvage therapy for the treatment of multidrug-resistant organisms:</p><p><br></p><p>Ceftolozane with tazobactam (Zerbaxa) for significant infections due to multidrug-resistant aerobic Gram-negative organisms, including <i>Pseudomonas aeruginosa</i> and extended spectrum beta-lactamase (ESBL)-producing <i>Enterobacteriaceae</i>.</p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee reviewed the following applications for salvage therapy for the treatment of multidrug-resistant organisms:</p><p><br></p><p>Ceftolozane with tazobactam (Zerbaxa) for significant infections due to multidrug-resistant aerobic Gram-negative organisms, including <i>Pseudomonas aeruginosa</i> and extended spectrum beta-lactamase (ESBL)-producing <i>Enterobacteriaceae</i>.</p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<p>https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-record-2019-05.pdf</p>', 'fs': '<p>https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-record-2019-05.pdf</p>', 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Anti-Infective Subcommittee at meeting Friday 10 May 2019.', 'fs': 'Clinical advice received from Anti-Infective Subcommittee at meeting Friday 10 May 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXXw2AP'}, 'Id': 'a0POZ00000FBXXw2AP', 'Event_Date__c': '2019-05-10', 'Event_Description__c': 'Clinical advice received from Anti-Infective Subcommittee at meeting Friday 10 May 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p>https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-record-2019-05.pdf</p>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'May 2019', 'Published_Recommendation__c': '<p><span style=""font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that ceftolozane with tazobactam (Zerbaxa) for significant infections due to multidrug-resistant aerobic Gram-negative organisms, including <i>Pseudomonas aeruginosa</i> and extended spectrum beta-lactamase (ESBL)-producing <i>Enterobacteriaceae</i>, be declined.</p>', 'Published_Application__c': '<p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee reviewed the following applications for salvage therapy for the treatment of multidrug-resistant organisms:</p><p><br></p><p>Ceftolozane with tazobactam (Zerbaxa) for significant infections due to multidrug-resistant aerobic Gram-negative organisms, including <i>Pseudomonas aeruginosa</i> and extended spectrum beta-lactamase (ESBL)-producing <i>Enterobacteriaceae</i>.</p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>Ceftolozane with tazobactam (Zerbaxa) for significant infections due to MDROs, including Ps. aeruginosa and ESBL-PE</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ceftolozane is a novel cephalosporin which exerts bactericidal activity through binding to penicillin-binding proteins, resulting in inhibition of bacterial cell-wall synthesis and subsequent cell death. The Subcommittee noted that tazobactam is a beta-lactam structurally related to penicillins.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ceftolozane and tazobactam are supplied as 1 g ceftolozane with 0.5 g tazobactam as powder for reconstitution for administration by IV infusion. The Subcommittee noted that ceftolozane and tazobactam are approved by Medsafe <span style=""color: black;"">for the treatment of adults with complicated intra-abdominal infections (in combination with metronidazole), or for complicated urinary tract infections including pyelonephritis.</span></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the pooled analysis of two phase III, randomised, double-blind trials investigating ceftolozane and tazobactam in patients with complicated urinary tract infections (ASPECT-cUTI trial) or complicated intra-abdominal infections (ASPECT-cIAI trial) which were reported by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27707990"" target=""_blank"">Popejoy et al. (J Antimicrob Chemother. 2017. 72:268-72</a>). The Subcommittee noted that the ASPECT-cUTI regimen was 7 days of ceftolozane with tazobactam compared to levofloxacin, and the ASPECT-cIAI regimen was 4-14 days of ceftolozane with tazobactam plus metronidazole compared to meropenem.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the pooled analysis included 1,346 patients of which 11% had EBSL-PE at baseline. The Subcommittee noted that reported clinical cure rates for patients with ESBL-PE were 97.4% with ceftolozane and tazobactam (<i>P=</i> 0.006) compared to cure rates of 82.6% for levofloxacin (<i>P</i>=0.011) and 88.5% with meropenem (<i>P</i>&gt;0.005). The Subcommittee considered that the randomised trial data demonstrated high clinical cure rates with ceftolozane and tazobactam treatment for complicated urinary tract infections and intra-abdominal infections caused by ESBL-PE.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following evidence for ceftolozane with tazobactam:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28610832"" target=""_blank"">Alatoom et al. Int J Infect Dis. 2017;62:39-43</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594953"" target=""_blank"">Escolà-Vergé et al. Infection. 2018;46:461-58</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29493397"" target=""_blank"">Giacobbe et al. Expert Rev Anti Infect Ther. 2018;16:307-320</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28735046"" target=""_blank"">Pfaller et al. J Glob Antimicrob Resist. 2017;10:186-194</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29039729"" target=""_blank"">Shortridge et al. Microb Drug Resist. 2018;24:563-77.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/25670823"" target=""_blank"">Solomkin et al. Clin Infect Dis. 2015;60:1462-71</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/25931244"" target=""_blank"">Wagenlehner et al. Lancet. 2015;385:1949-56</a>.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29133568"" target=""_blank"">Wi et al. Antimicrob Agents Chemother. 2017;62:e01970-17</a>.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that ceftolozane and tazobactam was safe and well tolerated. The Subcommittee considered that that the main indication for use of ceftolozane and tazobactam would be against <i>Ps. Aeruginosa</i> and that use of this combination of agents may be more suitable than combination treatment using ceftazidime with avibactam against this organism<i>.</i></p>', 'Status_History__c': 'a132P000000B42rQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2024', 'fs': 'Apr 2024', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXY12AP'}, 'Id': 'a0POZ00000FBXY12AP', 'Event_Date__c': '2024-04-30', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Apr 2024', 'Status_History__c': 'a13OZ00000CiRvFYAV'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2024', 'fs': 'May 2024', 'change': None}, 'Event_Description': {'s': 'Assigned to Anti-Infective Advisory Committee meeting to provide advice on Thursday 13 June 2024', 'fs': 'Assigned to Anti-Infective Advisory Committee meeting to provide advice on Thursday 13 June 2024', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXY22AP'}, 'Id': 'a0POZ00000FBXY22AP', 'Event_Date__c': '2024-05-15', 'Event_Description__c': 'Assigned to Anti-Infective Advisory Committee meeting to provide advice on Thursday 13 June 2024', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2024', 'Status_History__c': 'a13OZ00000DI31hYAD'}, 'change': None}, {'Summary': {'s': '<p>The Advisory Committee <strong>recommended</strong> that the suggested antimicrobials (ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, aztreonam-avibactam, and intravenous minocycline) be listed on Section H of the Pharmaceutical Schedule for MDRO infections, within the context of treatments for infections, subject to Hospital Restriction criteria.</p>', 'fs': '<p>The Advisory Committee <strong>recommended</strong> that the suggested antimicrobials (ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, aztreonam-avibactam, and intravenous minocycline) be listed on Section H of the Pharmaceutical Schedule for MDRO infections, within the context of treatments for infections, subject to Hospital Restriction criteria.</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2024-06-13-Anti-infectives-Advisory-Committee-Record.pdf#page=15"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2024-06-13-Anti-infectives-Advisory-Committee-Record.pdf#page=15"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Anti-Infective Advisory Committee at meeting Thursday 13 June 2024.', 'fs': 'Clinical advice received from Anti-Infective Advisory Committee at meeting Thursday 13 June 2024.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXY32AP'}, 'Id': 'a0POZ00000FBXY32AP', 'Event_Date__c': '2024-10-25', 'Event_Description__c': 'Clinical advice received from Anti-Infective Advisory Committee at meeting Thursday 13 June 2024.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2024-06-13-Anti-infectives-Advisory-Committee-Record.pdf#page=15"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': '<p>The Advisory Committee <strong>recommended</strong> that the suggested antimicrobials (ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, aztreonam-avibactam, and intravenous minocycline) be listed on Section H of the Pharmaceutical Schedule for MDRO infections, within the context of treatments for infections, subject to Hospital Restriction criteria.</p>', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000FoNk2YAF'}, 'change': None}]",May 2019,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2021', 'fs': 'May 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXXx2AP'}, 'Id': 'a0POZ00000FBXXx2AP', 'Event_Date__c': '2021-05-03', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2021', 'Status_History__c': 'a132P000000CoWMQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXY42AP'}, 'Id': 'a0POZ00000FBXY42AP', 'Event_Date__c': '2024-11-22', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000Gv6x7YAB'}, 'change': None}]",May 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2021', 'fs': 'May 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXXy2AP'}, 'Id': 'a0POZ00000FBXXy2AP', 'Event_Date__c': '2021-05-27', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'May 2021', 'Status_History__c': 'a132P000000Csg5QAC'}, 'change': None}]",May 2021,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXXz2AP'}, 'Id': 'a0POZ00000FBXXz2AP', 'Event_Date__c': '2023-12-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004kS3pYAE'}, 'change': None}]",Dec 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2024', 'fs': 'Feb 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000FBXY02AP'}, 'Id': 'a0POZ00000FBXY02AP', 'Event_Date__c': '2024-02-12', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Feb 2024', 'Status_History__c': 'a13OZ000006m8KnYAI'}, 'change': None}]",Feb 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
